BUSINESS COMBINATION AND DECONSOLIDATION OF SUBSIDIARY (Tables)

3 Months Ended

Mar. 31, 2022

BUSINESS COMBINATION AND DECONSOLIDATION OF SUBSIDIARY

Schedule of change in fair value of contingent consideration

(Dollars in thousands)	Fair Value of the Contingent Share Consideration
Fair value at December 31, 2020	$	3,205
Fair value at June 30, 2021		1,650
Net change in fair value for the six months ended June 30, 2021	$	(1,555	)

Schedule of estimated fair value of preliminary price

(Dollars in thousands)	Shares		Amount
Upfront Payment		-	$	1,000
Closing Merger Consideration Shares		6,909,091		9,535
Contingent Consideration Shares (Clawback Shares)		5,988,024		3,083
Liabilities assumed		-		550
Total purchase price		12,897,115	$	14,168

Schedule of preliminary estimated fair value of assets

(Dollars in thousands)
Net assets acquired:
Cash	$	1,357
Other assets		1,440
Property, plant and equipment		6
Other long term assets		384
Intangibles assets		10,182
Goodwill		4,687
Accounts payable and accrued expenses		(1,063	)
Contract liabilities		(1,963	)
Other current liabilities		(462	)
Other long-term liabilities		(400	)
Net assets acquired	$	14,168

Schedule identifiable intangible assets acquired

(Dollars in thousands)	Weighted-average Estimated useful life	Preliminary Estimated Asset Fair Value
Finite-lived intangible assets:
Customer relationships	5.0 years	$	7,110
Tradename	4.0 years	$	2,610
Non-compete	2.0 years	$	462
Total finite-lived intangible assets acquired	4.6 years	$	10,182

Schedule Acquisition

Dollars in thousands)	Fair Value of the Contingent Share Consideration
Fair Value at December 31, 2019	$	16,043
Settlement of contingent consideration liability		(21,701	)
Net change in fair value during the year ended December 31, 2020		5,658
Fair Value at December 31, 2020	$	-

Schedule Supplemental Pro Forma Information

	Cure Pharmaceutical			Sera Labs		Pro forma Adjustments		Consolidated Pro Forma
Net product sales	$	269		$	3,327	$	-	$	3,596
Net income (loss)	$	(13,349	)	$	4	$	-0.01	$	(13,345	)
Net income (loss) attributable to Cure per common share:, basic and diluted
Basic	$	(0.32	)	$	0.00			$	(0.25	)
Diluted	$	(0.32	)	$	0.00			$	(0.25	)

	Cure Pharmaceutical			Sera Labs			Pro forma Adjustments		Consolidated Pro Forma
Net product sales	$	549		$	3,940		$	-	$	4,489
Net loss	$	(11,392	)	$	(357	)	$	-	$	(11,749	)
Net loss attributable to Cure per common share:, basic and diluted
Basic	$	(0.29	)	$	(0.03	)			$	(0.23	)
Diluted	$	(0.29	)	$	(0.03	)			$	(0.23	)